UVA Licensing & Ventures Group
VC Fund
Charlottesville, United States
UVA Licensing & Ventures Group is an investment firm.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries UVA Licensing & Ventures Group invests in
Health CareBiotechnologyMedicalTherapeuticsMedical Device
Stages UVA Licensing & Ventures Group invests in
SeedSeries ASeries BFunding RoundSeries C
Countries UVA Licensing & Ventures Group invests in
United StatesEl Salvador
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Robert Creeden
|
|||
Andrew J. Krouse
|
|||
Investment Focus
Industry
- Health Care 5 (36%)
- Biotechnology 4 (29%)
- Medical 3 (21%)
- Therapeutics 3 (21%)
- Medical Device 3 (21%)
Stage
- Seed 6 (43%)
- Series A 2 (14%)
- Series B 2 (14%)
- Funding Round 2 (14%)
- Series C 1 (7%)
Country
- United States 9 (64%)
- El Salvador 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Robert Creeden
Managing Director
|
Managing Director | Total investments: 6 | Find email | |
|
Andrew J. Krouse
Entrepreneur-in-Residence
|
Entrepreneur-in-Residence | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NANOCHON
|
Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | $4M / Seed / May 06, 2024 | |
BrightSpec
|
LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia,about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research. | $18.4M / Series C / Dec 14, 2022 | |
GenEp
|
GenEp, Inc. is a pre-clinical stage biotechnology company based on intellectual property assets. GenEp creates therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies. | $1.5M / Seed / Oct 26, 2021 | |
|
NANOCHON
|
Nanochon is a biotech and medical device company specializing in the development of innovative orthopedic solutions. The company develops medical implant technology focused on cartilage repair for patients with joint surface damage. Its primary product, Chondrograft, is a 3D-printed, synthetic implant engineered to replace lost or damaged cartilageand support the body’s own tissue repair. The design uses a nylon-based composite with structural properties intended to mimic natural cartilage and fit securely into defects using a press-fit surgical procedure. Nanochon’s solution targets individuals who require more than temporary relief but are not yet candidates for total joint replacement, offering an off-the-shelf device that integrates with the healing process. The company’s work includes advancing clinical evaluation and surgical use of its implant technology. | $2M / Seed / Sep 16, 2021 | |
Mission Secure
|
Mission Secure®, an OT cybersecurity leader, is setting a new standard in OT cyber-protection stopping OT cyber threats head-on. The Mission Secure Platform backed by 24/7 Managed Services is the first to seamlessly integrate OT visibility, segmentation, protection, threat hunting, and incident response, delivering military strength,industrial grade OT protection. With Mission Secure, customers keep critical operations up and running and safe from harm. Learn more at https://www.missionsecure.com. | $5.6M / Series B / Jan 26, 2021 | |
Slate Bio
|
Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics. | $1.8M / Seed / Jan 19, 2021 | |
|
BrightSpec
|
LabBrightSpec addresses high-value, time-sensitive analytical chemistry challenges that are not well addressed by other spectroscopy techniques and instruments. It provides innovative laboratory services in order to deliver immediate results to potential customers of our instrumentation products. They are based in Charlottesville, Virginia,about two hours from Washington, DC. The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) product platform is based on technology developed at the University of Virginia by Brooks Pate and his team, several of whom now work at BrightSpec. They offer FT-MRR product configurations for analytical chemistry and gas sensing in manufacturing process control, quality control, environmental monitoring, and formulation research. | Series B / Aug 01, 2020 | |
|
Merand Pharmaceuticals
|
Merand Pharmaceuticals develops a microRNA therapeutic to treat Peripheral Arterial Disease. Merand's therapeutic treats patients by promoting angiogenesis or the development of new blood vessels, which leads to restored blood flow, enabling doctors to stabilize functional blood vessels of patients to increase perfusion recovery and reduceinflammation. | Seed / Jul 31, 2019 | |
|
Direct Spinal Therapeutics
|
Direct Spinal Therapeutics, Inc. operates in the healthcare industry focusing on biotechnology business. The company was incorporated in 2013 and is based in Charlottesville, Virginia. | Jun 18, 2019 | |
Arrive Health
|
RxRevu is a physician-founded organization on a mission to become the leader in prescription decision support, helping prescribers identify the most cost-effective medications for each patient, at the point of care. RxRevu was referred to as the “Google of Drugs” by CNBC and is currently working with health systems, PBMs, and electronic healthrecords (EHR) vendors.RxRevu’s EHR-embedded technology allows prescribers to view prior authorizations and real-time, patient-specific cost and drug options aligned with formulary and benefit data. This information is provided directly from the payer/PBM to inform the prescriber before medication selection. In addition, the platform provides prescription health analytics to help organizations understand prescribing behavior and drive consistent prescribing practices in line with an organization's best practices. | $15.9M / Series A / May 31, 2019 | |
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does UVA Licensing & Ventures Group invest in?
UVA Licensing & Ventures Group invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact UVA Licensing & Ventures Group?
Public channels for UVA Licensing & Ventures Group include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UVA Licensing & Ventures Group?
The team at UVA Licensing & Ventures Group includes Robert Creeden (Managing Director) and Andrew J. Krouse (Entrepreneur-in-Residence). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
